Enanta Pharmaceuticals Stock Performance

ENTA Stock  USD 13.89  0.03  0.22%   
Enanta Pharmaceuticals has a performance score of 1 on a scale of 0 to 100. The firm shows a Beta (market volatility) of -0.067, which means not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Enanta Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, Enanta Pharmaceuticals is likely to outperform the market. Enanta Pharmaceuticals right now shows a risk of 2.9%. Please confirm Enanta Pharmaceuticals semi deviation, sortino ratio, semi variance, as well as the relationship between the standard deviation and value at risk , to decide if Enanta Pharmaceuticals will be following its price patterns.

Risk-Adjusted Performance

Mild

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Enanta Pharmaceuticals are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite somewhat strong basic indicators, Enanta Pharmaceuticals is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors. ...more

Actual Historical Performance (%)

One Day Return
0.79
Five Day Return
1.16
Year To Date Return
(2.91)
Ten Year Return
(51.17)
All Time Return
(18.51)
1
Acquisition by Jay Luly of 310000 shares of Enanta Pharmaceuticals at 13.66 subject to Rule 16b-3
11/25/2025
2
Acquisition by Scott Rottinghaus of 110000 shares of Enanta Pharmaceuticals at 13.66 subject to Rule 16b-3
11/28/2025
3
Will Enanta Pharmaceuticals Inc. stock benefit from upcoming earnings reports - Rate Hike Accurate Technical Buy Alerts - Blm Sonu Canavar
12/19/2025
4
What makes Enanta Pharmaceuticals Inc. stock attractive to growth funds - Market Sentiment Extremes Minimal Capital Appreciation - Bollywood Helpline
12/23/2025
5
Enanta Pharmaceuticals, Inc. Receives 20.33 Average Price Target from Brokerages
12/29/2025
6
Enanta Pharmaceuticals Is Exploding On Watchlists But Is ENTA Stock Actually Worth Your Money - AD HOC NEWS
01/07/2026
7
JPM26 Enanta outlines strategy to lead in RSV therapeutics
01/15/2026
8
Enanta seeks 1.6M-share boost to 2019 equity plan - Stock Titan
01/26/2026
9
Enanta Pharmaceuticals Fiscal Q1 Earnings Snapshot
02/09/2026
10
Enanta Pharmaceuticals Quarterly Loss Narrows Yet Keeps Profitability Concerns In Investor Focus
02/11/2026
11
Enanta Pharmaceuticals, Inc. Given Average Recommendation of Moderate Buy by Analysts
02/12/2026
Begin Period Cash Flow41.2 M
Total Cashflows From Investing Activities40.3 M

Enanta Pharmaceuticals Relative Risk vs. Return Landscape

If you would invest  1,365  in Enanta Pharmaceuticals on November 22, 2025 and sell it today you would earn a total of  24.00  from holding Enanta Pharmaceuticals or generate 1.76% return on investment over 90 days. Enanta Pharmaceuticals is currently generating 0.0711% in daily expected returns and assumes 2.9001% risk (volatility on return distribution) over the 90 days horizon. In different words, 26% of stocks are less volatile than Enanta, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Enanta Pharmaceuticals is expected to generate 1.51 times less return on investment than the market. In addition to that, the company is 3.86 times more volatile than its market benchmark. It trades about 0.02 of its total potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.14 per unit of volatility.

Enanta Pharmaceuticals Target Price Odds to finish over Current Price

The tendency of Enanta Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 13.89 90 days 13.89 
about 47.23
Based on a normal probability distribution, the odds of Enanta Pharmaceuticals to move above the current price in 90 days from now is about 47.23 (This Enanta Pharmaceuticals probability density function shows the probability of Enanta Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Enanta Pharmaceuticals has a beta of -0.067 suggesting as returns on the benchmark increase, returns on holding Enanta Pharmaceuticals are expected to decrease at a much lower rate. During a bear market, however, Enanta Pharmaceuticals is likely to outperform the market. Additionally Enanta Pharmaceuticals has an alpha of 0.2718, implying that it can generate a 0.27 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   Enanta Pharmaceuticals Price Density   
       Price  

Predictive Modules for Enanta Pharmaceuticals

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Enanta Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Enanta Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
10.7413.7916.84
Details
Intrinsic
Valuation
LowRealHigh
12.5017.2120.26
Details
Naive
Forecast
LowNextHigh
10.6813.7316.78
Details
6 Analysts
Consensus
LowTargetHigh
18.4320.2522.48
Details

Enanta Pharmaceuticals Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Enanta Pharmaceuticals is not an exception. The market had few large corrections towards the Enanta Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Enanta Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Enanta Pharmaceuticals within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
0.27
β
Beta against Dow Jones-0.07
σ
Overall volatility
1.15
Ir
Information ratio 0.07

Enanta Pharmaceuticals Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Enanta Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Enanta Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Enanta Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 65.32 M. Net Loss for the year was (81.89 M) with profit before overhead, payroll, taxes, and interest of 66.98 M.
Enanta Pharmaceuticals currently holds about 253.29 M in cash with (19.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.22.
Enanta Pharmaceuticals has a poor financial position based on the latest SEC disclosures
Over 91.0% of the company shares are held by institutions such as insurance companies
Latest headline from thelincolnianonline.com: Enanta Pharmaceuticals, Inc. Given Average Recommendation of Moderate Buy by Analysts

Enanta Pharmaceuticals Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Enanta Stock often depends not only on the future outlook of the current and potential Enanta Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Enanta Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding21.3 M
Cash And Short Term Investments188.9 M

Enanta Pharmaceuticals Fundamentals Growth

Enanta Stock prices reflect investors' perceptions of the future prospects and financial health of Enanta Pharmaceuticals, and Enanta Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Enanta Stock performance.

About Enanta Pharmaceuticals Performance

By analyzing Enanta Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Enanta Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Enanta Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Enanta Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.34)(0.32)
Return On Capital Employed(0.42)(0.40)
Return On Assets(0.34)(0.32)
Return On Equity(1.46)(1.38)

Things to note about Enanta Pharmaceuticals performance evaluation

Checking the ongoing alerts about Enanta Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Enanta Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Enanta Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 65.32 M. Net Loss for the year was (81.89 M) with profit before overhead, payroll, taxes, and interest of 66.98 M.
Enanta Pharmaceuticals currently holds about 253.29 M in cash with (19.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.22.
Enanta Pharmaceuticals has a poor financial position based on the latest SEC disclosures
Over 91.0% of the company shares are held by institutions such as insurance companies
Latest headline from thelincolnianonline.com: Enanta Pharmaceuticals, Inc. Given Average Recommendation of Moderate Buy by Analysts
Evaluating Enanta Pharmaceuticals' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Enanta Pharmaceuticals' stock performance include:
  • Analyzing Enanta Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Enanta Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
  • Examining Enanta Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Enanta Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Enanta Pharmaceuticals' management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Enanta Pharmaceuticals' stock. These opinions can provide insight into Enanta Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Enanta Pharmaceuticals' stock performance is not an exact science, and many factors can impact Enanta Pharmaceuticals' stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Complementary Tools for Enanta Stock analysis

When running Enanta Pharmaceuticals' price analysis, check to measure Enanta Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enanta Pharmaceuticals is operating at the current time. Most of Enanta Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Enanta Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enanta Pharmaceuticals' price. Additionally, you may evaluate how the addition of Enanta Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.